<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629080</url>
  </required_header>
  <id_info>
    <org_study_id>H-100-002</org_study_id>
    <secondary_id>2017-005047-32</secondary_id>
    <nct_id>NCT03629080</nct_id>
  </id_info>
  <brief_title>A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients</brief_title>
  <official_title>A Randomized, Placebo-Control, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hookipa Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hookipa Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized,
      placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and
      efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a
      CMV-Seropositive living donor and CMV-Seropositive patients.Patients enrolled should have a
      living donor kidney transplantation ideally planned between two to four months after the
      first injection of study drug (HB-101 or placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity,
      immunogenicity, and efficacy of HB-101 in adult patients awaiting kidney transplantation. For
      Groups 1 and 2, adult CMV-seronegative (-) patients awaiting kidney transplant from a
      CMV-seropositive (+) living donor will be enrolled according to treatment intent with regard
      to the method of CMV prevention after transplant (either preemptive or prophylactic). This
      will be defined at study enrollment by the investigator and institutional standards. Patients
      enrolled in Group 1 and 2 will be randomized to receive HB-101 or placebo. For Group 3, adult
      CMV-seropositive (+) patients awaiting kidney transplant from either CMV-seropositive(+) or
      CMV-seronegative(-) living donors will be enrolled. Group 3 will be open label where all
      patients will receive HB-101. The post transplant management for Group 3 patients will also
      follow either preemptive or prophylactic method per the institution standards. The intent of
      the study is to administer three doses of the study drug (HB-101 or placebo) prior to
      transplantation and within proximity to the time of transplantation. However, two doses of
      study drug will be sufficient for the patients to be included in the efficacy analyses if a
      third dose of study drug is not feasible due to transplantation timelines. Patients will not
      receive study drug after transplantation. Patients will be recruited globally from transplant
      centers. The total duration of the study of each patient participating in the study will be
      approximately 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This phase 2 study will be conducted in three groups stratified by treatment intent. In Group 1, patients will be randomized to receive HB-101 (1a) or placebo (1b) and followed preemptively post-transplant. Approximately 50 patients will be randomized in Group 1. In Group 2, patients will be randomized to receive HB-101 (2a) or placebo (2b) before transplant. Post-transplant patients will receive 3-6 months of anti-viral prophylaxis following institutional standards. Approximately 100 patients will be randomized in Group 2. In Group 3, all patients will receive HB-101 (open label) vaccination(s) prior to their transplant surgery. Post-transplant CMV management will follow either preemptive or prophylactic care as defined at study enrollment by the investigator and institutional standards. Approximately 25 patients will be randomized in Group 3.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The participants, investigators and care providers (study site personnel) will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events from the time of first injection of study drug (3 months prior to transplant) up to 12 months post-transplant follow-up.</measure>
    <time_frame>15 months</time_frame>
    <description>For pre-transplant when study is administered: Evaluate the incidence of adverse events including clinical laboratory test variables (Complete Blood Count with differential, liver function tests, renal function tests) from the time of first injection of study drug up through 30 days after the last injection of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events of special interest from post-transplant (graft rejection, CMV syndrome and disease assessment) to the End of Study Visit.</measure>
    <time_frame>15 months</time_frame>
    <description>Evaluate the incidence of adverse events of special interest from post-transplant (graft rejection, CMV syndrome and disease) to the End of Study Visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Oral Body Temperature.</measure>
    <time_frame>3 Months</time_frame>
    <description>Measure Oral Body Temperature in degrees Celsius prior to study drug administrations and seven days after. Three doses of the study drug will be administered up to 3 months after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Heart Rate.</measure>
    <time_frame>3 Months</time_frame>
    <description>Measure heart rate in beats per minute prior to study drug administration and seven days after. Three doses of the study drug will be administered up to 3 months after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Respiration Rate.</measure>
    <time_frame>3 Months</time_frame>
    <description>Measure respiration rate in breaths per minute prior to study drug administration and seven days after. Three doses of the study drug will be administered up to 3 months after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Blood Pressure.</measure>
    <time_frame>3 Months</time_frame>
    <description>Measure Blood Pressure (diastolic and systolic) in mmHg prior to study drug administration and seven days after. Three doses of the study drug will be administered up to 3 months after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Weight.</measure>
    <time_frame>3 Months</time_frame>
    <description>Measure Weight in Kilograms prior to study drug administration and seven days after. Three doses of the study drug will be administered up to 3 months after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of local signs/symptoms of reactogenicity.</measure>
    <time_frame>3 Months</time_frame>
    <description>Assessment of local signs/symptoms of reactogenicity (administration site pain, tenderness, induration, erythema, redness, pruritus, or swelling) on treatment days for at least 60 minutes after study drug administration, and 7 days post-administration of study drug. Three doses of the study drug will be administered up to 3 months after randomization.
The severity of local signs/symptoms of reactogenity will be assigned as grade 1- 4, where increasing grade relates to increased severity, following the criteria listed in the FDA &quot;Guidance for Industry: Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventative Vaccine Trials.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular immunogenicity analyses the day of transplant and 3, 6 and 9 months after the transplant and at the end of study visit.</measure>
    <time_frame>12 Months</time_frame>
    <description>Cellular immunogenicity analyses will be conducted at the day of transplant, and 3, 6, 9 months after the transplant and at the end of study visit (a total of 12 months post-transplant follow up).
Cellular immunogenicity analyses of CMV pp65-specific interferon γ (IFN-γ), CMV gB-specific IFN-γ, CMV intracellular cytokine staining (ICS) pp65, CMV ICS gB, LCMV ELISPOT NP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Humoral immunogenicity analyses prior to the first dose of the study drug (3 months prior to transplant), on the day of transplant, and at the end of study visit (up to 12 months post-transplant follow-up).</measure>
    <time_frame>15 Months</time_frame>
    <description>Analysis of CMV-neutralization on MRC-5 cells and humoral immunogenicity of LCMV neutralizing using ELISPOT assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMV-neutralization on MRC-5 cells; (CMV neutralization).</measure>
    <time_frame>12 Months</time_frame>
    <description>Analysis of CMV-neutralization on MRC-5 cells; (CMV neutralization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of CMV DNAemia to assess the efficacy of HB-101 through 12 months after transplant.</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the incidence of CMV infection for 12 months since the day of transplant. The incidence will be assessed using polymerase chain reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The use of anti-CMV antivirals through 12 months after transplant.</measure>
    <time_frame>12 Months</time_frame>
    <description>Assess the use of antivirals used by measuring occurrence of anti-CMV antiviral therapy course for 12 months since the day of transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The magnitude of CMV DNAemia to assess the efficacy of HB-101 through 12 months after transplant.</measure>
    <time_frame>12 Months</time_frame>
    <description>Assess the magnitude of CMV infection for 12 months since the day of transplant. The magnitude will be assessed using polymerase chain reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of CMV DNAemia to assess the efficacy of HB-101 through 12 months after transplant.</measure>
    <time_frame>12 Months</time_frame>
    <description>Assess the duration of CMV infection for 12 months since the day of transplant. The duration will be assessed using polymerase chain reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of courses of CMV anti-viral therapy through 12 months after transplant.</measure>
    <time_frame>12 months</time_frame>
    <description>The efficacy of the administration of at least two doses of HB-101 compared to that of placebo in decreasing the use of anti-virals at treatment dose. The incidence of courses of CMV anti-viral therapy through 12 months after transplant will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of courses of CMV anti-viral therapy through 12 months after transplant.</measure>
    <time_frame>12 Months</time_frame>
    <description>The efficacy of the administration of at least two doses of HB-101 compared to that of placebo in decreasing the use of anti-virals at treatment dose. The duration of courses of CMV anti-viral therapy through 12 months after transplant will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of courses of CMV anti-viral therapy through 12 months after transplant.</measure>
    <time_frame>12 Months</time_frame>
    <description>The efficacy of the administration of at least two doses of HB-101 compared to that of placebo in decreasing the use of anti-virals at treatment dose. The number of courses of CMV anti-viral therapy through 12 months after transplant will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cytomegalovirus (CMV) Infection</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>HB-101 vaccine preemptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo preemptive</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB-101 vaccine prophylactic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo prophylactic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB-101 vaccine: CMV (+) patients-Prophylactic Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB-101 vaccine: CMV (+) patients-Preemptive Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-101 vaccine</intervention_name>
    <description>HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.</description>
    <arm_group_label>HB-101 vaccine preemptive</arm_group_label>
    <arm_group_label>HB-101 vaccine prophylactic</arm_group_label>
    <arm_group_label>HB-101 vaccine: CMV (+) patients-Preemptive Management</arm_group_label>
    <arm_group_label>HB-101 vaccine: CMV (+) patients-Prophylactic Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Saline will be used for placebo.</description>
    <arm_group_label>Placebo preemptive</arm_group_label>
    <arm_group_label>Placebo prophylactic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all of the following inclusion criteria will be eligible to participate
        in the study:

          1. Male or female patients 18 years of age or older.

          2. Patients must be eligible to undergo kidney transplantation from a living donor as per
             institutional standards.

          3. For Groups 1 and 2 only: Patients must be CMV immunoglobulin G (IgG) seronegative (-)
             and receiving kidney for transplantation from donors who are CMV IgG seropositive (+).

          4. For Group 3 only: Patients must be CMV immunoglobulin G (IgG) seropositive (+) and
             receiving kidney for transplantation from donors who are either CMV IgG seronegative
             (-) or seropositive (+).

          5. Patients who would comply with the requirements of this protocol (e.g., return for
             follow up visits), as judged by the investigator.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study:

          1. Patients planning to undergo multi-organ transplantation.

          2. Patients participating in another interventional clinical study.

          3. Previous vaccination with an investigational CMV vaccine.

          4. Any confirmed or suspected immunodeficiency disorder (based on medical history and
             physical examination) that could interfere with the immune response or that presents a
             risk for the patient to receive a vaccine candidate in development.

          5. Treatment with any chronic immunosuppressive medication or other immuno modifying
             drugs within 6 months prior to study entry. However, inhaled and topical steroids and
             low-dose oral corticosteroids (&lt;10 milligrams a day of prednisone or equivalent) are
             allowed.

          6. Prior history of CMV disease or CMV infection requiring anti-viral therapy

          7. Patients with a rash, dermatological condition, or tattoo in the area of the injection
             site(s) that could interfere with administration site reaction rating. (Note: The
             injection site(s) can be the non-dominant arm [most preferred injection site],
             dominant arm, or either thigh [least preferred injection site], as judged by the
             investigator).

          8. It is anticipated that the patient will be unavailable to complete the study
             follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Matushansky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hookipa Biotech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>General Hookipa contact</last_name>
    <phone>+43 1 890 6360 (EU)</phone>
    <email>office@hookipabiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>General Hookipa contact</last_name>
    <phone>+1-322-207-4590 (US)</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 1917 Clinic at UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Erdmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arman Faravardeh</last_name>
    </contact>
    <investigator>
      <last_name>Arman Faravardeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center Plaza</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suphamai Bunnapradist, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihung Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ram V Peddi</last_name>
      <phone>415-600-1092</phone>
      <email>PeddiR@Sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavio Vincenti</last_name>
      <email>flavio.Vincenti@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Davis</last_name>
      <email>scott.davis@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Marin</last_name>
      <phone>203-785-7595</phone>
      <email>ethan.marin@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beje Thomas</last_name>
      <phone>202-444-3700</phone>
      <email>beje.thomas@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University/IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William C Goggins</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Anne Dageforde</last_name>
      <email>LDAGEFORDE@MGH.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Bayudan Delos Santos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Alloway</last_name>
    </contact>
    <investigator>
      <last_name>Rita Alloway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati (UC) - College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Alloway</last_name>
    </contact>
    <investigator>
      <last_name>Rita Alloway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Chavin</last_name>
      <phone>216-844-2858</phone>
      <email>Kenneth.Chavin@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Hawxby</last_name>
      <email>alan.hawxby@oumedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas E. Starzl Transplantation Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhinav Humar, MD</last_name>
      <email>humara2@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wojciechowski</last_name>
      <email>david.wojciechowski@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjiv Anand</last_name>
      <email>Sanjiv.Anand@imail2.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidyanandh Vadivel</last_name>
      <email>Nidyanandh.Vadivel@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Oberbauer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Goffin</last_name>
    </contact>
    <investigator>
      <last_name>Eric Goffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian B Buhl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Merville</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Legendre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hospital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassim Kamar</last_name>
      <email>kamar.n@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klemens Budde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Witzke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan JL Bakker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luuk Hilbrands</last_name>
      <email>Luuk.Hilbrands@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjan van Zuilen</last_name>
      <email>a.vanzuilen@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dag Olav Dahle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Hill</last_name>
      <phone>44 (0)2895043216</phone>
      <email>christopher.hill@belfasttrust.hscni.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Chanouzas</last_name>
      <email>dimitrios.chanouzas@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS105NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rommel Ravanan</last_name>
      <phone>01174147698</phone>
      <email>Rommel.ravanan@nbt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiff &amp; Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sian Virginia Griffin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Daga</last_name>
      <email>sunildaga@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atul Bagul</last_name>
      <email>Atul.bagul@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Harber</last_name>
      <phone>+442077940500</phone>
      <email>mark.harber@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas's NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elham Asgari</last_name>
      <email>elham.asgari@gstt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muir Morton</last_name>
      <email>Muir.Morton@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>York Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith McCullough, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid organ transplantation</keyword>
  <keyword>vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

